# 1 A global atlas of genetic associations of 220 deep phenotypes

2

Saori Sakaue<sup>1-5, 46, \*</sup>, Masahiro Kanai<sup>1, 5-9, 46</sup>, Yosuke Tanigawa<sup>10</sup>, Juha Karjalainen<sup>5-7,9</sup>. Mitja 3 Kurki<sup>5-7,9</sup>, Seizo Koshiba<sup>11,12</sup>, Akira Narita<sup>11</sup>, Takahiro Konuma<sup>1</sup>, Kenichi Yamamoto<sup>1,13</sup>, 4 Masato Akiyama<sup>2,14</sup>, Kazuyoshi Ishigaki<sup>2-5</sup>, Akari Suzuki<sup>15</sup>, Ken Suzuki<sup>1</sup>, Wataru Obara<sup>16</sup>, 5 Ken Yamaji<sup>17</sup>, Kazuhisa Takahashi<sup>18</sup>, Satoshi Asai<sup>19,20</sup>, Yasuo Takahashi<sup>21</sup>, Takao 6 Suzuki<sup>22</sup>, Nobuaki Shinozaki<sup>22</sup>, Hiroki Yamaguchi<sup>23</sup>, Shiro Minami<sup>24</sup>, Shigeo Murayama<sup>25</sup>, 7 Kozo Yoshimori<sup>26</sup>, Satoshi Nagayama<sup>27</sup>, Daisuke Obata<sup>28</sup>, Masahiko Higashiyama<sup>29</sup>, 8 Akihide Masumoto<sup>30</sup>, Yukihiro Koretsune<sup>31</sup>, FinnGen, Kaoru Ito<sup>32</sup>, Chikashi Terao<sup>2</sup>, 9 Toshimasa Yamauchi<sup>33</sup>, Issei Komuro<sup>34</sup>, Takashi Kadowaki<sup>33</sup>, Gen Tamiya<sup>11,12,35,36</sup>, 10 Masayuki Yamamoto<sup>11,12,35</sup>, Yusuke Nakamura<sup>37,38</sup>, Michiaki Kubo<sup>39</sup>, Yoshinori Murakami<sup>40</sup>, 11 Kazuhiko Yamamoto<sup>15</sup>, Yoichiro Kamatani<sup>2,41</sup>, Aarno Palotie<sup>5,9,42</sup>, Manuel A. Rivas<sup>10</sup>, Mark J. 12 Dalv<sup>5-7,9</sup>. Koichi Matsuda<sup>43, \*</sup>. Yukinori Okada<sup>1,2,41,44,45, \*</sup> 13 14

Department of Statistical Genetics, Osaka University Graduate School of Medicine, Suita,
 Japan.

17 2. Laboratory for Statistical and Translational Genetics, RIKEN Center for Integrative

- 18 Medical Sciences, Yokohama, Japan
- 19 3. Center for Data Sciences, Harvard Medical School, Boston, MA, USA

20 4. Divisions of Genetics and Rheumatology, Department of Medicine, Brigham and
21 Women's Hospital, Harvard Medical School, Boston, MA, USA

- 5. Program in Medical and Population Genetics, Broad Institute of Harvard and MIT,Cambridge, MA, USA
- 6. Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA,USA

26 7. Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge,

- 27 MA, USA
- 28 8. Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA
- 29 9. Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
- 30 10. Department of Biomedical Data Science, School of Medicine, Stanford University,
- 31 Stanford, CA, USA
- 32 11. Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan
- 33 12. The Advanced Research Center for Innovations in Next-Generation Medicine (INGEM),
- 34 Sendai, Japan

- 13. Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan.
- 36 14. Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University,
- 37 Fukuoka, Japan
- 38 15. Laboratory for Autoimmune Diseases, RIKEN Center for Integrative Medical Sciences,
- 39 Yokohama, Japan
- 40 16. Department of Urology, Iwate Medical University, Iwate, Japan
- 41 17. Department of Internal Medicine and Rheumatology, Juntendo University Graduate
- 42 School of Medicine, Tokyo, Japan
- 43 18. Department of Respiratory Medicine, Juntendo University Graduate School of Medicine,
- 44 Tokyo, Japan
- 45 19. Division of Pharmacology, Department of Biomedical Science, Nihon University School
- 46 of Medicine, Tokyo, Japan
- 47 20. Division of Genomic Epidemiology and Clinical Trials, Clinical Trials Research Center,
- 48 Nihon University School of Medicine, Tokyo, Japan
- 49 21. Division of Genomic Epidemiology and Clinical Trials, Clinical Trials Research Center,
- 50 Nihon University School of Medicine, Tokyo, Japan
- 51 22. Tokushukai Group, Tokyo, Japan
- 52 23. Department of Hematology, Nippon Medical School, Tokyo, Japan
- 53 24. Department of Bioregulation, Nippon Medical School, Kawasaki, Japan
- 54 25. Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Tokyo, Japan
- 55 26. Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan
- 56 27. The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo,57 Japan
- 58 28. Center for Clinical Research and Advanced Medicine, Shiga University of Medical
- 59 Science, Otsu, Japan
- 60 29. Department of General Thoracic Surgery, Osaka International Cancer Institute, Osaka,
- 61 Japan
- 62 30. Aso lizuka Hospital, Fukuoka, Japan
- 63 31. National Hospital Organization Osaka National Hospital, Osaka, Japan
- 64 32. Laboratory for Cardiovascular Genomics and Informatics, RIKEN Center for Integrative
- 65 Medical Sciences, Yokohama, Japan
- 66 33. Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, The
- 67 University of Tokyo, Tokyo, Japan
- 68 34. Department of Cardiovascular Medicine, Graduate School of Medicine, The University of
- 69 Tokyo, Tokyo, Japan

- 70 35. Graduate School of Medicine, Tohoku University, Sendai, Japan
- 71 36. Center for Advanced Intelligence Project, RIKEN, Tokyo, Japan
- 72 37. Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo,
- 73 Japan
- 38. Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, Tokyo,
- 75 Japan
- 76 39. RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
- 40. Division of Molecular Pathology, Institute of Medical Science, The University of Tokyo,
- 78 Tokyo, Japan
- 79 41. Laboratory of Complex Trait Genomics, Department of Computational Biology and
- 80 Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo,
- 81 Japan
- 42. Psychiatric & Neurodevelopmental Genetics Unit, Department of Psychiatry, Analytic
- 83 and Translational Genetics Unit, Department of Medicine, and the Department of Neurology,
- 84 Massachusetts General Hospital, Boston, MA, USA
- 43. Department of Computational Biology and Medical Sciences, Graduate school of
- 86 Frontier Sciences, the University of Tokyo, Tokyo, Japan
- 87 44. Laboratory of Statistical Immunology, Immunology Frontier Research Center
- 88 (WPI-IFReC), Osaka University, Suita, Japan
- 89 45. Integrated Frontier Research for Medical Science Division, Institute for Open and
- 90 Transdisciplinary Research Initiatives, Osaka University, Suita, Japan
- 91 46. These authors contributed equally: S Sakaue and M Kanai.
- 92 \* Corresponding authors

Saori Sakaue, M.D., Ph.D. ssakaue@bwh.harvard.edu Center for Data Sciences, Harvard Medical School Koichi Matsuda, M.D., Ph.D. kmatsuda@edu.k.u-tokyo.ac.jp Department of Computational Biology and Medical Sciences, Graduate school of Frontier Sciences, The University of Tokyo Yukinori Okada, M.D., Ph.D. yokada@sg.med.osaka-u.ac.jp Department of Statistical Genetics, Osaka University Graduate School of Medicine

### 94 Abstract

95 Current genome-wide association studies (GWASs) do not yet capture sufficient diversity in 96 populations and scope of phenotypes. To expand an atlas of genetic associations in 97 non-European populations, we conducted 220 deep-phenotype GWASs (diseases, 98 biomarkers, and medication usage) in BioBank Japan (n=179,000), by incorporating past 99 medical history and text-mining of electronic medical records. Meta-analyses with the UK 100 Biobank and FinnGen (n<sub>total</sub>=628,000) identified ~5,000 novel loci, which improved the 101 resolution of genomic map of human traits. This atlas elucidated landscape of pleiotropy as 102 represented by MHC locus, where we conducted HLA fine-mapping. Finally, we performed 103 statistical decomposition of matrices of phenome-wide summary statistics, and identified 104 latent genetic components, which pinpointed responsible variants and biological 105 current disease classifications mechanisms underlying across populations. The 106 decomposed components enabled genetically-informed subtyping of similar diseases (e.g., 107 allergic diseases). Our study suggests a potential avenue for hypothesis-free 108 re-investigation of human diseases through genetics.

### 110 **Main**

#### 111 Introduction

112 Medical diagnosis has been shaped through description of organ dysfunctions and 113 extraction of shared key symptoms, which categorizes a group of individuals into a specific 114 disease to provide an optimal treatment. The earliest physicians in ancient Egypt empirically 115 made disease diagnoses based on clinical symptoms, palpitation, and auscultation (~2600 116 BC)<sup>1</sup>. Since then, physicians have refined the disease diagnosis by empirically categorizing 117 the observed symptoms (e.g., cough, sputum, and fever) to describe underlying dysfunction 118 (e.g., pneumonia, a lung infection). An increased understanding of organ functions and the 119 availability of diagnostic tests including biomarkers and imaging techniques have contributed to the current disease classifications, such as ICD10<sup>2</sup> and phecode<sup>3</sup>. 120

In the past decades, genome-wide association studies (GWASs)<sup>4</sup> and phenome-wide 121 122 association studies (PheWASs)<sup>5</sup> have provided novel insights into the biological basis 123 underlying disease diagnoses. While disease pathogenesis is guite multifactorial, genetic 124 underpinnings provide us with one way to independently assess the validity of historically-125 defined disease classifications. To this end, a comprehensive catalog of disease genetics is warranted. While previous works have broadly contributed the catalog<sup>6</sup>, current genetic 126 127 studies are still short of comprehensiveness in three ways; (i) population, in that the vast majority of GWASs have been predominated by European populations<sup>7</sup>, (ii) scope of 128 129 phenotypes, which were mostly limited to pre-determined diseases on which participants' 130 recruitment had been performed, and (iii) a systematic method to interpret a plethora of 131 summary results for understanding disease pathogenesis and epidemiology. We thus need

to promote equity in genetic studies by sharing the results of genetic studies of deepphenotypes from diverse populations.

134 To expand the atlas of genetic associations, here we conducted 220 deep-phenotype 135 GWASs in BioBank Japan (BBJ), including 108 phenotypes on which GWAS has never 136 been conducted in East Asian populations. We then conducted GWASs for corresponding 137 phenotypes in UK Biobank (UKB) and FinnGen, and performed cross-population 138 meta-analyses ( $n_{total}$ =628,000). We sought to elucidate the landscape of pleiotropy and genetic correlation across diseases and populations. Furthermore, we applied DeGAs<sup>8</sup> to 139 140 perform truncated singular-value decomposition (TSVD) on matrices of GWAS summary 141 statistics of 159 diseases each in Japanese and European ancestries, and derived latent 142 components shared across the diseases. We interpreted the derived components by (i) 143 functional annotation of genetic variants explaining the component, (ii) identification of 144 important cell types where the genes contributing to each component are specifically 145 regulated, and (iii) projection of GWASs of biomarkers or metabolomes into the component 146 space. The latent components recapitulated the hierarchy of current disease classifications, 147 while different diseases sometimes converged on the same component which implicated 148 shared biological pathways and relevant tissues. We classified a group of similar diseases 149 (e.g., allergic diseases) into subgroups based on these components. Analogous to the 150 conventional classification of diseases structured by the shared symptoms, an atlas of 151 genetic studies suggested the latent structure behind human diseases, which can elucidate 152 the genetic variants, genes, organs, and biological functions underlying human diseases.

153

### 154 Results

### 155 GWAS of 220 traits in BBJ and cross-population meta-analysis


156 Overview of this study is presented in **Extended Data Figure 1**. BBJ is a nationwide 157 biobank in Japan, and recruited participants based on the diagnosis of at least one of 47 target diseases (Supplementary Note)<sup>9</sup>. Along with the target disease status, deep 158 159 phenotype data, such as past medical history (PMH), drug prescription records (~7 million), 160 text data retrieved from electronic medical records (EMR), and biomarkers, have been 161 collected. Beyond the collection of case samples based on the pre-determined target 162 diseases, the PMH and EMR have provided broader insights into disease genetics, as shown in recently launched biobanks such as UKB<sup>10</sup> and BioVU<sup>11</sup>. We therefore curated the 163 164 PMH, performed text-mining of the EMR, and merged them with 47 target disease status.<sup>12</sup> 165 We created individual-level phenotypes on 159 disease endpoints (38 target diseases with 166 median 1.25 times increase in case samples and 121 novel disease endpoints) and 23 167 categories of medication usage. We then systematically mapped the disease endpoints into 168 phecode and ICD10, to enable harmonized GWASs in UKB and FinnGen. We also analyzed 169 a quantitative phenotype of 38 biomarkers in BBJ, of which individual phenotype data are 170 available in UKB<sup>13</sup>. Using genotypes imputed with the 1000 Genome Project phase 3 data 171 (n=2,504) and population-specific whole-genome sequencing data (n=1,037) as a reference 172 panel<sup>14</sup>, we conducted the GWASs of 159 binary disease endpoints, 38 biomarkers, and 23 173 medication usages in ~179,000 individuals in BBJ (Figure 1a-c, Supplementary Table 1 174 and 2 for phenotype summary). To maximize statistical power, we used a linear mixed model implemented in SAIGE<sup>15</sup> for binary traits and BOLT<sup>16</sup> for quantitative traits. By using 175 linkage disequilibrium (LD)-score regression<sup>17</sup>, we confirmed that potential biases were 176

177 controlled in the GWASs (Supplementary Table 3). In this expanded scope of GWASs in 178 the Japanese population, we identified 519 genome-wide significant loci across 159 disease 179 endpoints, 2,249 across 38 biomarkers, of which 113 and 281 loci were novel, respectively (P<5.0×10<sup>-8</sup>; see **Methods**, **Supplementary Table 4**). We conducted the initial 180 181 medication-usage GWASs in East Asian populations, and detected 215 genome-wide 182 significant loci across 23 traits (see Methods). These signals underscore the value of (i) 183 conducting GWASs in non-Europeans and (ii) expanding scope of phenotypes by 184 incorporating biobank resources such as PMH and EMR. For example, we detected an East 185 Asian-specific variant, rs140780894, at the MHC locus in pulmonary tuberculosis (PTB; Odds Ratio [OR]=1.2, P=2.9×10<sup>-23</sup>, Minor Allele Frequency[MAF]<sub>FAS</sub>=0.24; Extended Data 186 **Figure 2**), which was not present in European population (Minor Allele Count  $[MAC]_{FUR}=0$ )<sup>18</sup>. 187 PTB is a serious global health burden and relatively endemic in Japan<sup>19</sup> (annual incidence 188 189 per 100,000 was 14 in Japan whereas 8 in the United Kingdom and 3 in the United States in 190 2018 [World Health Organization, Global Tuberculosis Report]). Because PTB, an infectious 191 disease, can be treatable and remittable, we substantially increased the number of cases by 192 combining the participants with PMH of PTB to the patients with active PTB at the time of recruitment (from 549<sup>12</sup> to 7,800 case individuals). We also identified novel signals in 193 194 common diseases that had not been target diseases but were included in the PMH record. 195 such as rs715 at 3'UTR of CPS1 in cholelithiasis (Extended Data Figure 3; OR=0.87,  $P=9.6\times10^{-13}$ ) and rs2976397 at the PSCA locus in gastric ulcer, gastric cancer, and gastric 196 polyp (**Extended Data Figure 4**; OR=0.86, *P*=6.1×10<sup>-24</sup> for gastric ulcer). We detected 197 198 pleiotropic functional variants, such as a deleterious missense variant, rs28362459 (p.Leu20Arg), in FUT3 associated with gallbladder polyp (OR=1.46, P=5.1×10<sup>-11</sup>) and 199

cholelithiasis (OR=1.11, P=7.3×10<sup>-9</sup>; Extended Data Figure 5), and a splice donor variant, 200 201 rs56043070 (c.89+1G>A), causing loss of function of GCSAML associated with urticaria (OR=1.24, P=6.9×10<sup>-12</sup>; Extended Data Figure 6), which was previously reported to be 202 203 associated with platelet and reticulocyte counts<sup>4</sup>. Medication-usage GWASs also provided interesting signals as an alternative perspective for understanding disease genetics<sup>20</sup>. For 204 205 example, individuals taking HMG CoA reductase inhibitors (C10AA in Anatomical 206 Therapeutic Chemical Classification [ATC]) were likely to harbor variations at HMGCR (lead variant at rs4704210, OR=1.11, P=2.0×10<sup>-27</sup>). Prescription of salicylic acids and derivatives 207 208 (N02BA in ATC) were significantly associated with a rare East Asian missense variant in  $P=7.1\times10^{-11}$ 209 PCSK9. rs151193009 (p.Arg93Cvs; OR=0.75,  $MAF_{FAS} = 0.0089$ , 210 MAF<sub>FUR</sub>=0.000; **Extended Data Figure 7**), which might indicate a strong protective effect 211 against thromboembolic diseases in general.

212 We next conducted GWASs of corresponding phenotypes (i.e., disease endpoints and 213 biomarkers) which can be mapped in UKB and FinnGen (196 and 128 traits, respectively; 214 see **Methods**), and collected summary statistics of medication usage GWAS conducted in UKB<sup>20</sup> (23 traits; Supplementary Table 5). To confirm that the signals identified in BBJ 215 216 were reasonable, we systematically compared the effect sizes of the genome-wide 217 significant variants in BBJ with those in a European dataset across binary and quantitative 218 traits (see **Methods**). The loci identified in BBJ GWASs were successfully validated in the same effect direction (2,171 out of 2,305 [94.2%], P<10<sup>-325</sup> in sign test) and with high 219 220 effect-size correlation (**Extended Data Figure 8**). We also note that the genetic correlations 221 encompassing genome-wide polygenic signals were generally high between BBJ and 222 European GWASs (median  $\rho_{qe}=0.82$ ; Supplementary Table 6, see Methods).

223 Motivated by the high replicability, we performed cross-population meta-analyses of 224 these 220 harmonized phenotypes across three biobanks (see Methods). We identified 225 1,730 disease-associated, 12,066 biomarker-associated, and 1,018 medication-associated 226 loci in total, of which 571, 4,471, and 301 were novel, respectively (Figure 1d, 227 **Supplementary Table 7**). We note that when we strictly control for multiple testing burden by Bonferroni correction ( $P < 5.0 \times 10^{-8}$  / (220 phenotypes  $\times$  3 populations)=7.6 $\times 10^{-11}$ ), the 228 229 number of significantly associated loci was 844, 7,309, and 500, respectively. All these 230 summary statistics of GWASs are openly distributed through PheWeb.jp website, with 231 interactive Manhattan plots, Locus Zoom plots, and PheWAS plots based on PheWeb 232 platform<sup>21</sup>. Together, we successfully expanded the genomic map of human complex traits 233 in terms of populations and scope of phenotypes through conducting deep-phenotype 234 GWASs across cross-population nationwide biobanks.



236

Figure 1. Overview of the identified loci in the cross-population meta-analyses of 220
 deep phenotype GWASs.


(a-c) The pie charts describe the phenotypes analyzed in this study. The disease endpoints (a;  $n_{\text{trait}}=159$ ) were categorized based on the ICD10 classifications (A to Z; **Supplementary Table 1a**), the biomarkers (b;  $n_{\text{trait}}=38$ ; **Supplementary Table 1b**) were classified into nine categories, and medication usage was categorized based on the ATC system (A to S; **Supplementary Table 1c**). (d) The genome-wide significant loci identified in the cross-population meta-analyses and pleiotropic loci ( $P < 5.0 \times 10^{-8}$ ). The traits (rows) are

- sorted as shown in the pie chart, and each dot represents significant loci in each trait.
- 246 Pleiotropic loci are annotated by lines with a locus symbol.

# 248 The regional landscape of pleiotropy.

249 Because human traits are highly polygenic and the observed variations within human 250 genome are finite in number, pleiotropy, where a single variant affects multiple traits, is 251 pervasive<sup>22</sup>. While pleiotropy has been intensively studied in European populations by compiling previous GWASs<sup>22-25</sup>, the landscape of pleiotropy in non-European populations 252 253 has been understudied. By leveraging this opportunity for comparing the genetics of deep 254 phenotypes across populations, we sought to investigate the landscape of regional 255 pleiotropy in both Japanese and European populations. We defined the degree of pleiotropy as the number of significant associations per variant  $(P < 5.0 \times 10^{-8})^{23}$ . In the Japanese, rs671, 256 257 a missense variant at the ALDH2 locus, harbored the largest number of genome-wide 258 significant associations (47 traits; Figure 2a). Following this, rs2523559 at the MHC locus 259 (24 traits) and rs1260326 at the GCKR locus (20 traits) were most pleiotropic. In Europeans, 260 rs9265949 at the MHC locus harbored the largest number of genome-wide significant 261 associations (46 traits; Figure 2b), followed by rs7310615 at the ATXN2/SH2B3 locus (38 262 traits), rs1260326 at the GCKR locus (28 traits), and rs2519093 at ABO locus (28 traits). We 263 note that those pleiotropic loci were not affected when we adjusted for phenotypically closely 264 correlated traits (Extended Data Figure 9,10) or genetically closely related traits (Extended 265 **Data Figure 10**, methods in **Supplementary Note**). Notably, the *ALDH2* locus (pleiotropic in 266 Japanese) and the MHC locus (pleiotropic in Japanese and Europeans) are known to be under recent positive selection<sup>26,27</sup>. To systematically assess whether pleiotropic regions in 267 268 the genome were likely to be under selection pressure in each of the populations, we 269 investigated the enrichment of the signatures of recent positive selection quantified by the metric singleton density score (SDS)<sup>26</sup> values within the pleiotropic loci (see Methods). 270

Intriguingly, when compared with those under the null hypothesis, we observed significantly higher values of SDS  $\chi^2$  values within the pleiotropic loci, and this fold change increased as the number of associations increased (i.e., more pleiotropic) in both Japanese and Europeans (**Figure 2c** and **2d**). To summarize, the cross-population atlas of genetic associations elucidated the broadly shared landscape of pleiotropy, which implied a potential connection to natural selection signatures affecting human populations.



279 Figure 2. Number of significant associations per variant.

(a, b) The Manhattan-like plots show the number of significant associations ( $P < 5.0 \times 10^{-8}$ ) at each tested genetic variant for all traits ( $n_{\text{trait}}=220$ ) in Japanese (a) and in European GWASs (b). Loci with a large number of associations were annotated based on the closest genes of each variant. (c, d) The plots indicate the fold change of the sum of SDS  $\chi^2$  within variants with a larger number of significant associations than a given number on the x-axis compared with those under the null hypothesis in Japanese (c) and in Europeans (d). We also illustrated a regression line based on local polynomial regression fitting.


### 288 Pleiotropic associations in HLA and ABO locus.

289 Given the high degree of pleiotropy in both populations, we next sought to fine-map the 290 pleiotropic signals within the MHC locus. To this end, we imputed the classical HLA alleles in 291 BBJ and UKB, and performed association tests for 159 disease endpoints and 38 292 biomarkers (Figure 3a and 3b). After the fine-mapping and conditional analyses (see 293 Methods), we identified 75 and 129 independent association signals in BBJ and UKB, respectively (P<5.0×10<sup>-8</sup>; **Supplementary Table 8**). Among 53 and 63 traits associated with 294 295 MHC in BBJ and UKB, 2 and 9 traits had never been previously shown to be associated with 296 MHC, respectively. Overall, HLA-B in class I and HLA-DRB1 in class II harbored the largest 297 number of associations in both BBJ and UKB. For example, we fine-mapped the strong signal associated with PTB to HLA-DRβ1 Ser57 (OR=1.20, P=7.1×10<sup>-19</sup>) in BBJ. This is the 298 299 third line of evidence showing the robust association of HLA with tuberculosis identified to 300 date<sup>28,29</sup>, and we newly fine-mapped the signal to *HLA-DRB1*. Interestingly, HLA-DRB1 at 301 position 57 also showed pleiotropic associations with other autoimmune and thyroid-related 302 diseases, such as Grave's disease (GD), hyperthyroidism, Hashimoto's disease, Sjögren's 303 syndrome, chronic hepatitis B, and atopic dermatitis in BBJ. Of note, the effect direction of 304 the association of HLA-DRβ1 Ser57 was the same between hyperthyroid status (OR=1.29,  $P=2.6\times10^{-14}$  in GD and OR=1.37,  $P=1.4\times10^{-8}$  in hyperthyroidism) and hypothyroid status 305 (OR=1.50, P=9.0×10<sup>-8</sup> in Hashimoto's disease and OR=1.31), despite the opposite direction 306 307 of thyroid hormone abnormality. This association of HLA-DRB1 was also observed in Sjogren's syndrome (OR=2.04,  $P=7.9\times10^{-12}$ ), which might underlie epidemiological 308 comorbidities of these diseases<sup>30</sup>. Other novel associations in BBJ included HLA-DR<sup>β</sup>1 309

Asn197 with sarcoidosis (OR=2.07, P=3.7×10<sup>-8</sup>), and four independent signals with chronic sinusitis (i.e., *HLA-DRA*, *HLA-B*, *HLA-A*, and *HLA-DQA1*).

Another representative pleiotropic locus in the human genome is the *ABO* locus. We performed ABO blood-type PheWAS in BBJ and UKB (**Figure 3c** and **3d**). We estimated the

- 314 ABO blood type from three variants (rs8176747, rs8176746, and rs8176719 at 9q34.2)<sup>31</sup>,
- 315 and associated them with the risk of diseases and quantitative traits for each blood group. A
- 316 variety of phenotypes, including common diseases such as myocardial infarction as well as
- biomarkers such as blood cell traits and lipids, were associated with the blood types in both
- biobanks (Supplementary Table 9). We replicated an increased risk of gastric cancer in
- 319 blood-type A as well as an increased risk of gastric ulcer in blood-type O in BBJ<sup>32</sup>.



321

### 322 Figure 3. HLA and ABO association PheWAS.

323 (a,b) Significantly associated HLA genes identified by HLA PheWAS in BBJ (a) or in UKB (b) are plotted ( $P < 5.0 \times 10^{-8}$ ). In addition to primary association signals of the phenotypes, 324 325 independent associations identified by conditional analyses are also plotted, and the primary 326 association is indicated by the plots with a gray border. The color of each plot indicates 327 two-tailed *P* values calculated with logistic regression (for binary traits) or linear regression 328 (for quantitative traits) as designated in the color bar at the bottom. The bars in green at the 329 top indicate the number of significant associations per gene in each of the populations. The 330 detailed allelic or amino acid position as well as statistics in the association are provided in 331 Supplementary Table 8.

- 332 (c,d) Significant associations identified by ABO blood-type PheWAS in BBJ (c) or in UKB (d)
- 333 are shown as boxes and colored based on the odds ratio. The size of each box indicates
- two-tailed *P* values calculated with logistic regression (for binary traits) or linear regression
- 335 (for quantitative traits).
- 336

### 337 Genetic correlation elucidates the shared phenotypic domains across populations.

338 The interplay between polygenicity and pleiotropy suggests widespread genetic correlations 339 among complex human traits<sup>33</sup>. Genetic relationships among human diseases have contributed to the refinement of disease classifications<sup>34</sup> and elucidation of the biology 340 underlying the epidemiological comorbidity<sup>33</sup>. To obtain insights into the interconnections 341 342 among human traits and compare them across populations, we computed pairwise genetic 343 correlations ( $r_0$ ) across 106 traits (in Japanese) and 148 traits (in Europeans) with Z-score 344 for  $h_{SNP}^2$ , using bivariate LD score regression (see **Methods**). We then defined the 345 correlated trait domains by greedily searching for the phenotype blocks with pairwise  $r_{a}$ >0.7 346 within 70% of  $r_{a}$  values in the block on the hierarchically clustered matrix of pairwise  $r_{a}$ 347 values (**Extended Data Figure 11**). We detected domains of tightly correlated phenotypes, 348 such as (i) cardiovascular- acting medications, (ii) coronary artery disease, (iii) type 2 349 diabetes- related phenotypes, (iv) allergy- related phenotypes, and (v) blood-cell phenotypes 350 in BBJ (Extended Data Figure 11a). These domains implicated the shared genetic 351 backgrounds on the similar diseases and their treatments (e.g., (ii) diseases of the 352 circulatory system in ICD10 and their treatments) and diagnostic biomarkers (e.g., (iii) 353 glucose and HbA1c in type 2 diabetes). Intriguingly, the corresponding trait domains were 354 mostly identified in UKB as well (Extended Data Figure 11b). We considered that the 355 current clinical boundaries for human diseases might broadly reflect the shared genetic 356 etiology across populations, despite differences in populations and despite potential 357 differences in diagnostic, environmental, and prescription practices.

358

# 359 Deconvolution of a matrix of summary statistics of 159 diseases provides novel 360 insights into disease pathogenesis.

361 A major challenge in genetic correlation is that the  $r_{q}$  is a scalar value between two traits, 362 which collapses the correlation over the whole genome into an averaged metric<sup>35</sup>. This 363 approach is not straightforward in specifying a set of genetic variants driving the observed 364 correlation, which would pinpoint biological pathways explaining the shared pathogenesis. 365 To address this, genetic association statistics of diverse phenotypes can implicate latent 366 structures underlying genotype-phenotype associations without a prior hypothesis. In particular, matrix decomposition of GWAS statistics is a promising approach<sup>8,36,37</sup>, which 367 368 derives orthogonal components that explain association variance across multiple traits. This 369 decomposition addresses two challenges in current genetic correlation studies. First, it 370 informs us of genetic variants that explain the shared structure across multiple diseases, 371 thereby enabling functional interpretation of the component. Second, it can be applicable to 372 sub-significant associations, which are important in understanding contribution of common 373 variants in rare diseases<sup>36</sup> or in genetic studies in underrepresented populations where 374 lower statistical power is inevitable.

Therefore, we applied DeGAs<sup>8</sup> on a matrix of the disease GWAS summary statistics in Japanese and Europeans ( $n_{disease}$ =159; **Figure 4a** and **4b**). To interpret the derived latent components, we annotated the genetic variants explaining each component (i) through GREAT genomic region ontology enrichment analysis<sup>38</sup>, (ii) through identification of relevant cell types using tissue specific regulatory DNA (ENCODE3<sup>39</sup>) and expression (GTEx<sup>40</sup>) profiles, and (iii) by projecting biomarker GWASs in BBJ and UKB ( $n_{biomarker}$ =38) or metabolome GWASs in EAS cohort of Tohoku Medical Megabank Organization (ToMMo;

Methods) and EUR cohort<sup>41</sup> (*n*<sub>metabolite\_EAS</sub>=206, *n*<sub>metabolite\_EUR</sub>=248) into the component space derived from disease genetics (**Figure 4a**). We applied TSVD on the sparse Z score matrix of 22,980 variants, 159 phenotypes each in 2 populations (Japanese and Europeans), and derived 40 components that together explained 36.7% of the variance (**Extended Data Figure 12, 13**).

387 Globally, similar diseases as defined by the conventional ICD10 classification were 388 explained by the same components, based on DeGAs trait squared cosine scores that quantifies component loadings<sup>8</sup> (Figure 4c, d). This would be considered as a 389 390 hypothesis-free support of the historically defined disease classifications. For example, 391 component 1 explained the genetic association patterns of diabetes (E10 and E11 in ICD10) 392 and component 2 explained those of cardiac and vascular diseases (100-183), in both 393 populations. Functional annotation of the genetic variants explaining these components 394 showed that component 1 (diabetes component) was associated with abnormal pancreas size (binomial  $P_{\text{enrichment}} = 7.7 \times 10^{-19}$ ) as a human phenotype, whereas component 2 395 396 (cardiovascular disease component) was associated with xanthelasma (i.e., cholesterol accumulation on the eyelids; binomial  $P_{\text{enrichment}} = 3.0 \times 10^{-10}$ ). Further, the genes comprising 397 398 component 1 were enriched in genes specifically expressed in the pancreas (Penrichment  $=5.5 \times 10^{-4}$ ), and those comprising component 2 were enriched in genes specifically 399 400 expressed in the aorta ( $P_{enrichment} = 1.9 \times 10^{-3}$ ; **Extended Data Figure 14**). By projecting the 401 biomarker GWASs in BBJ and UKB and the metabolite GWASs in independent cohorts of 402 EAS and EUR into this component space, we observed that component 1 represented the 403 genetics of glucose and HbA1c, and component 2 represented the genetics of blood 404 pressure and lipids, which are biologically relevant. This deconvolution-projection analyses

suggested the latent genetic structure behind human diseases, which recapitulated theunderlying biological functions, relevant tissues, and associated markers.


407 The latent components shared across diseases explained the convergent biology 408 behind etiologically similar diseases. For example, component 10 explained the genetics of 409 cholelithiasis (gall stone), cholecystitis (inflammation of gallbladder), and gall bladder polyp 410 (Figure 4e). The projection of publicly available EUR metabolite GWASs into the component 411 space identified that component 10 represented the bilirubin metabolism pathway. 412 Component 10 was composed of variants involved in intestinal cholesterol absorption in 413 mouse phenotype (binomial  $P_{enrichment}=3.8\times10^{-10}$ ). This is biologically relevant, since 414 increased absorption of intestinal cholesterol is a major cause of cholelithiasis, which also causes cholecystitis<sup>42</sup>. The projection of the metabolite GWASs in independent Japanese 415 416 cohort of ToMMo showed the connection between the component 10 and glycine that 417 conjugates with bile acids<sup>43</sup>.

418 Some components were further utilized to interpret the underpowered GWAS with the 419 use of well-powered GWAS, and to identify the contributor of shared genetics between 420 different diseases. For example, we complemented underpowered varicose GWAS in BBJ 421  $(n_{case}=474, genome-wide significant loci=0)$  with more powered GWAS in Europeans 422  $(n_{case}=22.037, \text{ genome-wide significant loci=70})$ . Both GWASs were mostly represented by 423 component 11, which was explained by variants related to abnormal vascular development (binomial  $P_{\text{enrichment}}=4.2\times10^{-7}$ ; Figure 4f). Another example is component 27, which was 424 425 shared with rheumatoid arthritis and systemic lupus erythematosus, two distinct but 426 representative autoimmune diseases. Component 27 was explained by the variants associated with interleukin secretion and plasma cell number (binomial  $P_{\text{enrichment}}=6.1\times10^{-10}$ 427

and  $9.3 \times 10^{-10}$ , respectively), and significantly enriched in the DNase I hypersensitive site (DHS) signature of lymphoid tissue ( $P_{enrichment}=1.3 \times 10^{-4}$ ; **Figure 4g**). This might suggest the convergent etiology of the two autoimmune diseases, which was not elucidated by the genetic correlation alone.

432 Finally, we aimed at hypothesis-free categorization of diseases based on these 433 components. Historically, hypersensitivity reactions have been classified into four types (e.g., types I to IV)<sup>44</sup>, but the clear sub-categorization of allergic diseases based on this 434 435 pathogenesis and whether the categorization can be achieved solely by genetics were 436 unknown. In TSVD results, the allergic diseases (mostly J and L in ICD10) were represented 437 by the four components 3, 16, 26, and 34. By combining these components as axis-1 438 (components 3 and 16) and axis-2 (components 26 and 34), and comparing the cumulative 439 variance explained by these axes, we defined axis-1 dominant allergic diseases (e.g., 440 asthma and allergic rhinitis) and axis-2 dominant allergic diseases (metal allergy, contact 441 dermatitis, and atopic dermatitis; Figure 4h). Intriguingly, the axis-1 dominant diseases 442 etiologically corresponded to type I allergy (i.e., immediate hypersensitivity). The variants 443 explaining axis-1 were biologically related to IgE secretion and Th<sub>2</sub> cells (binomial  $P_{\text{enrichment}}=9.9\times10^{-46}$  and  $2.9\times10^{-44}$ , respectively). Furthermore, GWAS of eosinophil count 444 was projected onto axis-1, which recapitulated the biology of type I allergy<sup>45</sup>. In contrast, the 445 446 axis-2 dominant diseases corresponded to type IV allergy (i.e., cell-mediated delayed 447 hypersensitivity). The variants explaining axis-2 were associated with IL-13 and interferon secretion (binomial  $P_{\text{enrichment}}=1.6\times10^{-10}$  and  $5.2\times10^{-9}$ , respectively), and GWAS of 448 C-reactive protein was projected onto axis-2, which was distinct from  $axis-1^{46}$ . To 449 450 summarize, our deconvolution approach (i) recapitulated the existing disease classifications,

- 451 (ii) implicated underlying biological mechanisms and relevant tissues shared among related
- 452 diseases, and (iii) suggested potential application for genetics-driven categorization of
- 453 human diseases.
- 454
- 455



456

Figure 4. The deconvolution analysis of a matrix of summary statistics of 159
 diseases across populations.

(a) An illustrative overview of deconvolution-projection analysis. Using DeGAs framework, a
matrix of summary statistics from two populations (EUR: European and BBJ: Biobank
Japan) was decomposed into latent components, which were interpreted by annotation of a

462 set of genetic variants driving each component and in the context of other GWASs through 463 projection. (b) A schematic representation of TSVD applied to decompose a summary 464 statistic matrix **W** to derive latent components. **U**, **S**, and **V** represent resulting matrices of 465 singular values (S) and singular vectors (U and V). (c) A heatmap representation of DeGAs 466 squared cosine scores of diseases (columns) to components (rows). The components are 467 shown from 1 (top) to 40 (bottom), and diseases are sorted based on the contribution of 468 each component to the disease measured by the squared cosine score (from component 1 469 to 40). Full results with disease and component labels are in Extended Data Figure 15. 470 (d) Results of TSVD of disease genetics matrix and the projection of biomarker genetics. 471 Diseases (left) and biomarkers (right) are colored based on the ICD10 classification and 472 functional categorization, respectively. The derived components (middle; from 1 to 40) are 473 colored alternately in blue or red. The squared cosine score of each disease to each 474 component and each biomarker to each component is shown as red and blue lines. The 475 width of the lines indicates the degree of contribution. The diseases with squared cosine 476 score>0.3 in at least one component are displayed. Anth; anthropometry, BP; blood 477 pressure, Metab; metabolic, Prot; protein, Kidn; kidney-related, Ele; Electrolytes, Liver; 478 liver-related, Infl; Inflammatory, BC; blood cell. (e-h) Examples of disease-component 479 correspondence and biological interpretation of the components by projection and 480 enrichment analysis using GREAT. A representative component explaining a group of 481 diseases based on the contribution score, along with responsible genes, functional 482 enrichment results GREAT, relevant tissues, and relevant biobarkers/metabolites is shown. 483 GB; gallbladder. RA; rheumatoid arthritis. SLE; systemic lupus erythematosus.

484

### 485 **Discussion**

486 Here, we performed 220 GWASs of human traits by incorporating the PMH and EMR data in 487 BBJ, substantially expanding the atlas of genotype-phenotype associations in 488 non-Europeans. We note that we additionally discovered 92 loci across 38 disease endpoints of which we had previously conducted GWASs in BBJ<sup>12</sup>, which highlights the 489 490 value of curating PMH and EMR in biobanks. We then systematically compared their genetic 491 basis with GWASs of corresponding phenotypes in Europeans. We confirmed the global 492 replication of loci identified in BBJ, and discovered 5,343 novel loci through cross-population 493 meta-analyses, highlighting the value of conducting GWASs in diverse populations. The 494 results are openly shared through web resources, which will be a platform to accelerate 495 further research such as functional follow-up studies and drug discovery<sup>47</sup>. Of note, 496 leveraging these well-powered GWASs, we observed that the genes associated with 497 endocrine/metabolic, circulatory, and respiratory diseases (E, I, and J by ICD10) were 498 systematically enriched in targets of approved medications treating those diseases<sup>48</sup> 499 (Extended Data Figure 16). This should motivate us to use this expanded resource for 500 genetics-driven novel drug discovery and drug repositioning.

The landscape of regional pleiotropy was globally shared across populations, and pleiotropic regions tended to have been under recent positive selection. One limitation of the current analysis is that we did not conduct statistical fine-mapping for every locus we identified, which might cause a concern over potential effects due to LD tagging for observed pleiotropy. Although we confirmed that the same pleiotropic variants were included within the 95% credible set for representative loci (*ALDH2* and *GCKR*; see **Supplementary Note**), more comprehensive statistical fine-mapping would further illuminate a global landscape of

508 pleiotropic variants in the future. Moreover, elucidation of pleiotropy in other populations is 509 warranted to replicate our results. To highlight the utility of deep phenotype GWASs, we 510 decomposed the cross-population genotype–phenotype association patterns by TSVD. The 511 latent components derived from TSVD showed the convergent biological mechanisms and 512 relevant cell types across diseases, which can be utilized for re-evaluation of existing 513 disease classifications. The incorporation of biomarker and metabolome GWAS summary 514 statistics enabled interpretation of the latent components. Our approach might suggest a 515 potential avenue for restructuring of medical diagnoses through dissecting the shared 516 genetic basis across a spectrum of diseases, as analogous to the current disease 517 classifications historically and empirically shaped through categorization of key symptoms 518 across a spectrum of organ dysfunctions. However, we note that one major challenge in the 519 deconvolution analyses is that the derived components and their order are affected by 520 selection of phenotypes analyzed as input matrices. Thus, external validations are 521 necessary before being generalized and used for refinement of disease categorization.

In conclusion, our study substantially expanded the atlas of genetic associations,
supported the historically-defined categories of human diseases, and should accelerate the
discovery of the biological basis contributing to complex human diseases.

525

526

### 527 Acknowledgments

528 We sincerely thank all the participants of BioBank Japan, UK Biobank, and FinnGen. We 529 thank Dr. Kyoko Watanabe for her input in the analysis of phenotypic correlations and 530 pleiotropy. This research was supported by the Tailor-Made Medical Treatment program

531 (the BioBank Japan Project) of the Ministry of Education, Culture, Sports, Science, and 532 Technology (MEXT), the Japan Agency for Medical Research and Development (AMED). 533 The FinnGen project is funded by two grants from Business Finland (HUS 4685/31/2016 and 534 UH 4386/31/2016) and nine industry partners (AbbVie, AstraZeneca, Biogen, Celgene, 535 Genentech, GSK, MSD, Pfizer and Sanofi). Following biobanks are acknowledged for 536 collecting the FinnGen project samples: Auria Biobank (https://www.auria.fi/biopankki/), THL 537 Biobank (https://thl.fi/fi/web/thl-biopank), Helsinki Biobank 538 (https://www.terveyskyla.fi/helsinginbiopankki/), Northern Finland Biobank Borealis 539 (https://www.ppshp.fi/Tutkimus-ja-opetus/Biopankki), Finnish Clinical Biobank Tampere 540 (https://www.tays.fi/biopankki), Biobank of Eastern Finland (https://ita-suomenbiopankki.fi), 541 Central Finland Biobank (https://www.ksshp.fi/fi-FI/Potilaalle/Biopankki), Finnish Red Cross 542 Blood Service Biobank (https://www.bloodservice.fi/Research%20Projects/biobanking), 543 Tervevstalo Biobank Finland (https://www.terveystalo.com/fi/Yritystietoa/Terveystalo-Biopankki/Biopankki/). S.S. was in 544 545 part supported by The Mochida Memorial Foundation for Medical and Pharmaceutical 546 Research, Kanae Foundation for the promotion of medical science, Astellas Foundation for 547 Research on Metabolic Disorder, and The JCR Grant for Promoting Basic Rheumatology . 548 M.Kanai was supported by a Nakajima Foundation Fellowship and the Masason Foundation. 549 Y.Tanigawa is in part supported by a Funai Overseas Scholarship from the Funai 550 Foundation for Information Technology and the Stanford University School of Medicine. 551 M.A.R. is in part supported by National Human Genome Research Institute (NHGRI) of the 552 National Institutes of Health (NIH) under award R01HG010140 (M.A.R.), and a National 553 Institute of Health center for Multi- and Cross-population Mapping of Mendelian and

554 Complex Diseases grant (5U01 HG009080). The content is solely the responsibility of the 555 authors and does not necessarily represent the official views of the National Institutes of 556 Health. Y.O. was supported by the Japan Society for the Promotion of Science (JSPS) 557 KAKENHI (19H01021, 20K21834), and AMED (JP20km0405211, JP20ek0109413, 558 JP20ek0410075, JP20gm4010006, and JP20km0405217), Takeda Science Foundation, 559 and Bioinformatics Initiative of Osaka University Graduate School of Medicine, Osaka 560 University.

561

### 562 Author Contributions

563 S.S., M. Kanai, and Y.O. conceived the study. S.S., M. Kanai, Y. Tanigawa, M.A.R., and Y.O. wrote the manuscript. S.S., M. Kanai, J.K., M. Kurki, T.Konuma, Kenichi Yamamoto, 564 565 M.A., K.Ishigaki, Kazuhiko Yamamoto, Y. Kamatani, A.P., M.J.D., and Y.O. conducted 566 GWAS data studies. S.S., Y. Tanigawa., and M.A.R. conducted statistical decomposition 567 analysis. S.S., S.T., A.N., G.T., and Y.O. conducted metabolome analysis. A.S., K.S., W.O., 568 Ken Yamaji, K.T., S.A., Y.Takahashi, T.S., N.S., H.Y., S.Minami, S.Murayama, Kozo 569 Yoshimori, S.N., D.O., M.H., A.M., Y.Koretsune, K.Ito, C.T., T.Y., I.K., T.Kadowaki, M.Y., 570 Y.N., M.Kubo, Y.M., Kazuhiko Yamamoto, and K.M. collected and managed samples and 571 data. A.P. and M.J.D. coordinated collaboration with FinnGen.

572

### 573 Competing Financial Interests

574 M.A.R. is on the SAB of 54Gene and Computational Advisory Board for Goldfinch Bio and 575 has advised BioMarin, Third Rock Ventures, MazeTx and Related Sciences. The funders

576 had no role in study design, data collection and analysis, decision to publish, or preparation577 of the manuscript.

578

### 579 Data availability

580 The genotype data of BBJ used in this study are available from the Japanese 581 Genotype-phenotype Archive (JGA; http://trace.ddbj.nig.ac.jp/jga/index e.html) with 582 accession code JGAD0000000123 and JGAS0000000114. The UKB analysis was 583 conducted via application number 47821. This study used the FinnGen release 3 data. All 584 summary statistics of 220 GWASs (BioBank Japan, European, and cross-population 585 meta-analyses) are deposited at the National Bioscience Database Center (NBDC) Human 586 Database with the accession code hum0197. We also provide an interactive visualization of 587 Manhattan, Locus Zoom, and PheWAS plots with downloadable GWAS summary statistics 588 at our PheWeb.jp website [https://pheweb.jp/]. The summary statistics of metabolite GWASs 589 in the Japanese population (Tohoku Medical Megabank Organization) are being prepared 590 as a different project. The previous version of the partial statistics is publicly available at 591 https://jmorp.megabank.tohoku.ac.jp/202008/gwas/TGA000003.

592

### 593 Code availability

594 We used publicly available software for the analyses. The used software is listed and 595 described in the **Method** section of our manuscript.

596

### 597 Methods

### 598 Genome-wide association study of 220 traits in BBJ

599 We conducted 220 deep phenotype GWASs in BBJ. BBJ is a prospective biobank that 600 collaboratively collected DNA and serum samples from 12 medical institutions in Japan and 601 recruited approximately 200,000 participants, mainly of Japanese ancestry (Supplementary 602 **Note**). All study participants had been diagnosed with one or more of 47 target diseases by 603 physicians at the cooperating hospitals. We previously conducted GWASs of 42 out of the 47 target diseases<sup>12</sup>. In this study, we newly curated the PMH records included in the clinical 604 605 data, and performed text-mining to retrieve disease records from the free-format EMR as 606 well. For disease phenotyping, PMH record has already been curated and formatted as 607 sample x phenotype table. Regarding EMR, we searched for Japanese term of a given 608 disease diagnosis in the cells designated as the presence of PMH, which was compiled into 609 sample x phenotype table. We merged both information with the target disease status, and 610 defined the case status for 159 diseases with a case count>50 (Supplementary Table 2). 611 As controls, we used samples in the cohort without a given diagnosis or related diagnoses, which was systematically defined by using the phecode framework<sup>3</sup> (Supplementary Table 612 613 1). For medication-usage phenotyping, we again retrieved information by text-mining of 614 7,018,972 medication records. Then, we categorized each medication trade name by using 615 the ATC (Anatomical Therapeutic Chemical Classification), World Health Organization, 616 which is used for the classification of active ingredients of drugs according to the organ or 617 system on which they act and their therapeutic, pharmacological and chemical properties. 618 For biomarker phenotyping, we used the same processing and quality control method as previously described (Supplementary Table 2 for phenotype summary)<sup>13,49</sup>. In brief, we 619

620 generally used the laboratory values measured at the participants' first visit to the 621 recruitment center, and excluded measurements outside three times of interguartile range 622 (IQR) of upper/lower quartile across participants. For individuals taking anti-hypertensive 623 medications, we added 15 mmHg to systolic blood pressure (SBP) and 10 mmHg to diastolic 624 blood pressure (DBP). For individuals taking a statin, we applied the following correction to 625 the lipid measurements: i) Total cholesterol was divided by 0.8; ii) measured LDL-cholesterol 626 (LDLC) was adjusted as LDLC / 0.7; iii) derived LDLC from the Friedewald was re-derived as 627 (Total cholesterol / 0.8) - HDLC - (Triglyceride/ 5).

628 We genotyped participants with the Illumina HumanOmniExpressExome BeadChip or a 629 combination of the Illumina HumanOmniExpress and HumanExome BeadChips. Quality 630 control of participants and genotypes was performed as described elsewhere<sup>14</sup>. In this 631 project, we analyzed 178,726 participants of East Asian ancestry as estimated by the 632 principal component analysis (PCA)-based sample selection criteria. The genotype data 633 were further imputed with 1000 Genomes Project Phase 3 version 5 genotype (n=2,504) and 634 Japanese whole-genome sequencing data (n=1,037) using Minimac3 software. After this 635 imputation, we excluded variants with an imputation quality of Rsq<0.7, resulting in 636 13,530,797 variants analyzed in total.

We conducted GWASs for binary traits (i.e., disease endpoints and medication usage) by using a generalized linear mixed model implemented in SAIGE (version 0.37), which had substantial advantages in terms of (i) maximizing the sample size by including genetically related participants, and (ii) controlling for case–control imbalance<sup>15</sup>, which was the case in many of the disease endpoints in this study. We included adjustments for age, age<sup>2</sup>, sex, age×sex, age<sup>2</sup>×sex, and top 20 principal components for as covariates used in step 1. For

643 sex-specific diseases, we alternatively adjusted for age, age<sup>2</sup>, and the top 20 principal 644 components as covariates used in step 1, and we used only controls of the sex to which the 645 disease is specific. We conducted GWASs for quantitative traits (i.e., biomarkers) by using a 646 linear mixed model implemented in BOLT-LMM (version 2.3.4). We included the same 647 covariates as used in the binary traits above.

648 All the participants provided written informed consent approved from ethics committees 649 of the Institute of Medical Sciences, the University of Tokyo and RIKEN Center for 650 Integrative Medical Sciences.

651

# 652 Harmonized genome-wide association study of 220 traits in UKB and FinnGen

653 We conducted the GWASs harmonized with BBJ in UKB and in FinnGen. The UK Biobank 654 project is a population-based prospective cohort that recruited approximately 500,000 655 people across the United Kingdom (Supplementary Note). We defined case and control 656 status of 158 disease endpoints, which were originally retrieved from the clinical information 657 in UKB and mapped to BBJ phenotypes via phecode (Supplementary Table 1). We also 658 analyzed 38 biomarker values provided by the UKB. The genotyping was performed using 659 either the Applied Biosystems UK BiLEVE Axiom Array or the Applied Biosystems UK 660 Biobank Axiom Array. The genotypes were further imputed using a combination of the 661 Haplotype Reference Consortium, UK10K, and 1000 Genomes Phase 3 reference panels by IMPUTE4 software<sup>10</sup>. In this study, we analyzed 361,194 individuals of white British genetic 662 663 ancestry as determined by the PCA-based sample selection criteria (see URLs). We 664 excluded the variants with (i) INFO score  $\leq 0.8$ , (ii) MAF  $\leq 0.0001$  (except for missense and protein-truncating variants annotated by VEP<sup>50</sup>, which were excluded if MAF  $\leq$  1 × 10<sup>-6</sup>), and 665

(iii)  $P_{HWF} \leq 1 \times 10^{-10}$ , resulting in 13,791,467 variants analyzed in total. We conducted 666 667 GWASs for 159 disease endpoints by using SAIGE with the same covariates used in the 668 BBJ GWAS. For biomarker GWASs, we used publicly available summary statistics of UKB 669 biomarker GWAS when available (see URLs), and otherwise performed linear regression 670 using PLINK software with the same covariates, excluding the genetically related individuals (the 1st, 2nd, or 3rd degree)<sup>10</sup>. For medication usage GWASs, we used publicly available 671 summary statistics of medication usage in UKB<sup>20</sup>, which was organized by the ATC and thus 672 673 could be harmonized with BBJ GWASs.

674 FinnGen is a public-private partnership project combining genotype data from Finnish 675 biobanks and digital health record data from Finnish health registries (Supplementary 676 **Notes**). For GWASs, we used the summary statistics of FinnGen release 3 data (see **URLs**). 677 The disease endpoints were mapped to BBJ phenotypes by using ICD10 code, and we 678 defined 128 out of 159 endpoints in BBJ. The genome coordinates in summary statistics 679 were lifted over to hg19, and we analyzed 16,859,359 variants after QC. We did not conduct 680 biomarker and medication-related GWASs because the availability of these phenotypes was 681 limited.

682

683 *Meta-analysis, definition of significant loci, and annotation of the lead variants with* 684 *genome-wide significance* 

First, we performed intra-European meta-analysis when summary statistics of both UKB and FinnGen were available, and then performed cross-population meta-analysis across three or two cohorts in 159 disease endpoints, 38 biomarker values, and 23 medication usage GWASs. We conducted these meta-analyses by using the inverse-variance method and

estimated heterogeneity with Cochran's Q test with METAL software<sup>51</sup>. In this meta-analysis,
we included all variants after QC in each of the three cohorts. The overlapping variants
among the cohorts are summarized in **Extended Data Figure 17**. The summary statistics of
primary GWASs in BBJ and cross-population meta-analysis GWASs are openly shared
without any restrictions.

We adopted the conventional genome-wide significance threshold of  $< 5.0 \times 10^{-8}$ , as well as considering the Bonferroni-corrected threshold of  $< 7.6 \times 10^{-11}$  ( $5.0 \times 10^{-8}$  / (220 phenotypes  $\times$  3 populations)) in the context of cross-population meta-analysis. We defined independent genome-wide significant loci on the basis of genomic positions within ±500 kb from the lead variant. We considered a trait-associated locus as novel when the locus within ±1 Mb from the lead variant did not include any variants that were previously reported to be significantly associated with the same disease.

To systematically collect previously reported significant associations  $(5.0 \times 10^{-8})$  as known variants, we

- exhaustively searched for previous reports of genetic association in a given trait
   using the GWAS Catalog<sup>4</sup>, since it is currently recognized as a standard and
   most comprehensive database of genetic associations,
- 7062. systematically searched PubMed when the corresponding trait was not included707 in GWAS Catalog, and
- 3. exceptionally included preprints in case we have collaboratively worked on them,
  in order to avoid duplicated publication.

The goal was to comprehensively include only robust and invariant associations. In this way, we included 75,230 associations across 181 traits in 1,792 literatures as of December

712 31, 2020 (**Supplementary Table 10**).

We annotated the lead variants using ANNOVAR software, such as rsIDs in dbSNP database (see **URLs**), the genomic region and closest genes, and functional consequences. We also supplemented this with the gnomAD database<sup>18</sup>, and also looked for the allele frequencies in global populations as an independent resource.

717

# 718 Replication of significant associations in BBJ

For 2,287 lead variants in the genome-wide significant loci of 159 disease endpoints and 38 biomarkers in BBJ, we compared the effect sizes and directions with European-only meta-analysis when available and with UKB-based summary statistics otherwise. Of them, 1,929 variants could be compared with the corresponding European GWASs. Thus, we performed the Pearson's correlation test for these variants' beta in the association test in BBJ and in European GWAS. We also performed the correlation tests with variants with  $P_{EUR}<0.05$  and to those with  $P_{EUR}<5.0\times10^{-8}$ .

726

### 727 Cross-population genetic correlation

To estimate cross-population genetic-effect correlations between BBJ and European GWASs considering polygenic signals, we used Popcorn software (version 1.0)<sup>52</sup>. For this analysis, we restricted the traits to those with (i) heritability Z score from LDSC>2 (which will be explained later in **Methods**), and (ii) both BBJ and European heritability calculated by Popcorn>0.01. We excluded the MHC region from the analysis because of its complex LD structure. Using these QCed traits' summary statistics, we calculated the cross-population
 genetic-effect correlation between EUR and EAS with precomputed cross-population scores

for EUR and EAS 1000 Genomes populations provided by the authors.

736

737 Evaluation of regional pleiotropy

We assessed the regional pleiotropy based on each tested genetic variant separately for BBJ GWASs and for European GWASs (i.e., intra- European meta-analysis when FinnGen GWAS was available and UKB summary statistics otherwise). We quantified the degree of pleiotropy per genetic variant by aggregating and counting the number of genome-wide significant associations across 220 traits. We then annotated loci from the largest number of associations ( $n_{associations} \ge 9$  in BBJ and  $\ge 18$  in Europeans) in **Figure 2a**, **b**.

744 Next, we assessed the recent natural selection signature within the pleiotropic loci 745 separately for Japanese and for Europeans. To do this, we first defined the pleiotropic loci 746 by identifying genetic variants that harbored a larger number of significant associations than 747 a given threshold. We varied this threshold from 1 to 40. Then, at each threshold, we calculated the sum of SDS  $\chi^2$  values within the pleiotropic loci, and compared this with the  $\chi^2$ 748 749 distribution under the null hypothesis with a degree of freedom equal to the number of 750 variants in the loci. We thus estimated the SDS enrichment within the pleiotropic loci defined 751 by a given threshold as fold change and P value. The SDS values were obtained from the 752 web resource indicated in the original article on Europeans (see URLs) and provided by the authors on Japanese<sup>27</sup>. The raw SDS values were normalized according to the derived allele 753 754 frequency as described previously.

# 756 Fine-mapping of HLA and ABO loci

We performed the fine-mapping of MHC associations in BBJ and UKB by HLA imputation<sup>53</sup>. 757 758 In BBJ, we imputed classical HLA alleles and corresponding amino acid sequences using 759 the reference panel recently constructed from 1,120 individuals of Japanese ancestry by the 760 combination of SNP2HLA software, Eagle, and minimac3, as described previously<sup>54</sup>. We 761 applied post-imputation quality control to keep the imputed variants with minor allele 762 frequency (MAF)  $\geq$  0.5% and Rsq>0.7. For each marker dosage that indicated the presence 763 or absence of an investigated HLA allele or an amino acid sequence, we performed an 764 association test with the disease endpoints and biomarkers. We assumed additive effects of 765 the allele dosages on phenotypes in the regression models. We included the same 766 covariates as in the GWAS. In UKB, we imputed classical HLA alleles and corresponding amino acid sequences using the T1DGC reference panel of European ancestry (n=5,225)<sup>55</sup>. 767 768 We applied the same post-imputation quality control and performed the association tests as 769 in BBJ.

770

#### 771 Heritability and genetic correlation estimation

We performed LD score regression (see **URLs**) for GWASs of BBJ and Europeans to estimate SNP-based heritability, potential bias, and pairwise genetic correlations. Variants in the MHC region (chromosome 6:25–34  $\square$ Mb) were excluded. We also excluded variants with  $\chi^2 \square > \square 80$ , as recommended previously<sup>56</sup>. For heritability estimation, we used the baselineLD model (version 2.2), which included 97 annotations that correct for bias in heritability estimates<sup>57</sup>. We note that we did not report liability-scale heritability, since population prevalence of 159 diseases in each country was not always available, and the main

objective of this analysis was an assessment of bias in GWAS, rather than the accurate estimation of heritability. We calculated the heritability Z-score to assess the reliability of heritability estimation, and reported the LDSC results with Z-score for  $h^2_{SNP}$  is>2 (**Supplementary Table 3**). For calculating pairwise genetic correlation, we again restricted the target GWASs to those whose Z-score for  $h^2_{SNP}$  is>2, as recommended previously<sup>56</sup>. In total, we calculated genetic correlation for 106 GWASs in BBJ and 148 in European GWASs, which resulted in 5,565 and 10,878 trait pairs, respectively.

786 To illustrate trait-by-trait genetic correlation, we hierarchically clustered the  $r_{g}$  values with 787 hclust and colored them as a heatmap (Extended Data Figure 11). To adopt reliable 788 genetic correlations, we restricted the  $r_{q}$  values that had  $P_{cor} < 0.05$ . Otherwise, the  $r_{q}$  values 789 were replaced with 0. We then defined the tightly clustered trait domains by greedily 790 searching for the phenotype blocks with pairwise  $r_q > 0.7$  within 70% of  $r_q$  values in the block 791 from the top left of the clustered correlation matrix. We manually annotated each trait 792 domain by extracting the characteristics of traits constituting the domain (Extended Data 793 Figure 11).

794

795 Deconvolution of a matrix of summary statistics by TSVD

We performed the TSVD on the matrix of genotype-phenotype association Z scores as described previously as DeGAs framework<sup>8</sup>. In this study, we first focused on 159 disease endpoint GWASs in BBJ and European GWAS (i.e., 318 in total) to derive latent components through TSVD. On constructing a Z-score matrix, we conducted variant-level QC. We removed variants located in the MHC region (chromosome 6: 25–34 Mb), and

801 replaced unreliable Z-score estimates with zero when one of the following conditions were

- 802 satisfied as in Tanigawa et al.<sup>8</sup>:
- 803 P value of marginal association  $\ge 0.001$
- 804 Standard error of beta value  $\ge 0.2$

805 Considering that rows and columns with all zeros do not contribute to matrix decomposition. 806 we excluded variants that had all zero Z-scores across 159 traits in either in BBJ or Europeans. We then performed LD pruning using PLINK software<sup>58</sup> ("--indep-pairwise 50 5 807 808 0.1") with an LD reference of 5,000 randomly selected individuals of white British UKB 809 participants to select LD-independent variant sets, which resulted in a total of 22,980 810 variants. Thus, we made a Z-score matrix (=  $\mathbf{W}$ ) with a size of 318 (N: 159 diseases x 2 811 populations)  $\times$  22,980 (*M*: variants). With a predetermined number of *K*. TSVD decomposed W into a product of three matrices: U, S, and V<sup>T</sup>: W = USV<sup>T</sup>. U =  $(u_{i,k})_{i,k}$  is an 812 813 orthonormal matrix of size  $N \square \times \square K$  whose columns are phenotype singular vectors, **S** is a diagonal matrix of size  $K \square \times \square K$  whose elements are singular values, and  $\mathbf{V} \square = \square (v_{i,k})_{i,k}$  is an 814 orthonormal matrix of size  $M \square x \square K$  whose columns are variant singular vectors. Here we set 815 816 K as 40, which together explained 36.7% of the total variance of the original matrix. This 817 value was determined by experimenting with different values from 20 to 100 and selecting 818 the informative and sufficient threshold. We used the TruncatedSVD module in the 819 sklearn.decomposition library of python for performing TSVD.

To interpret and visualize the results of TSVD, we calculated the squared cosine scores. The phenotype squared cosine score,  $cos_i^{2^{phe}}(k)$ , is a metric to quantify the relative importance of the *k*th latent component for a given phenotype *i*, and is defined as follows;

$$cos_{i}^{2^{phe}}(k) = \frac{(f_{i,k}^{p})^{2}}{\sum_{k'}(f_{i,k'}^{p})^{2}}$$

823 where

824 
$$\mathbf{F}_p = \mathbf{U}\mathbf{S} = \left(f_{i,k}^p\right)_{i,k}.$$

825

Annotation of the components by using GREAT and identification of relevant cell types
We calculated the variant contribution score, which is a metric to quantify the contribution of

828 a given variant *j* to a given component *k* as follows;

$$contr_k^{var}(j) = (v_{i,k})^2$$

829 For each component, we can thus rank the variants based on their contribution to the 830 component and calculate the cumulative contribution score. We defined a set of *contributing* 831 variants to a given component to include top-ranked variants that had high contribution 832 scores until the cumulative contribution score to the component exceeded 0.5. For these 833 variant sets contributing to the latent components, we performed the GREAT (version 4.0.4) binomial genomic region enrichment analysis<sup>38</sup> based on the size of the regulatory domain 834 835 of genes and quantified the significance of enrichment in terms of binomial fold enrichment 836 and binomial P value to biologically interpret these components. We used the human 837 phenotype and mouse genome informatics phenotype ontology, which contains manually 838 curated knowledge about the hierarchical structure of phenotypes and genotype-phenotype 839 mapping of human and mouse, respectively. The enriched annotation with a false discovery 840 rate (FDR)<0.05 is considered significant and displayed in the figures.

For a gene set associated with the contributing variants with a given component (P< 0.05), we sought to identify relevant cell types by integrating two datasets: (i) ENCODE3

843 DHS regulatory patterns across human tissues from non-negative matrix factorization (NFM)<sup>39</sup> and (ii) specifically expressed genes defined from GTEx data<sup>40</sup>. In brief, a 844 845 vocabulary (i.e., DHS patterns) for regulatory patterns was defined from the NFM of 3 million 846 DHSs x 733 human biosamples encompassing 438 cell and tissue types. Then, for each 847 regulatory vocabulary, GENCODE genes were assigned based on their overlying DHSs. The gene labeling result was downloaded from the journal website<sup>39</sup>. We also defined genes 848 849 specifically expressed in 53 tissues from GTEx version 7 data, based on the top 5% of the tstatistics in each tissue as described elsewhere<sup>59</sup>. Then, for (i) each regulatory vocabulary 850 851 and (ii) each tissue, we performed Fisher's exact tests to investigate whether the genes 852 associated with a given component are significantly enriched in the defined gene set.

853

### 854 Projection of biomarker and metabolite GWASs into the component space

To further help interpret the latent components derived from disease-based TSVD, we projected the Z-score matrix of biomarker GWASs and metabolite GWASs into the component space. Briefly, we constructed the Z-score matrices (**W**') of 38 biomarkers of BBJ and European GWASs (i.e., 76 rows) and 248 known metabolites of independent previous GWASs in the European population<sup>41</sup> × 22,980 variants (**Supplementary Table 11**). Then, using the **V** from the disease-based TSVD, we calculated the phenotype contribution as follows;

$$\mathbf{F}_{p}^{projection} = \mathbf{W}'\mathbf{V} = \left(f_{i,k}^{projection}\right)_{i,k}$$

We note that for metabolite GWASs, since the GWASs were imputed with the HapMap reference panel, we imputed Z-scores of missing variants using ssimp software<sup>60</sup> (version 0.5.5 --ref 1KG/EUR --impute.maf 0.01), and otherwise we set the missing Z-scores to zero.

865

## 866 Projection of Metabolite GWASs in Japanese into the component space

867 To investigate whether the projection analysis is applicable to independent dataset, we 868 conducted metabolite GWASs in ToMMo. ToMMo is a community-based biobank that 869 combines medical and genome information from the participants in the Tohoku region of Japan<sup>61</sup>. Detailed cohort description is presented in **Supplementary Notes**. In this study, 870 we analyzed a total of 206 metabolites<sup>62</sup> measured by proton nuclear magnetic resonance 871 872 (NMR) or liquid chromatography (LC)-MS (Supplementary Table 12). For sample QC, we 873 excluded samples meeting any of the following criteria: (1) genotype call rate<95%, (2) one individual from each pair of those in close genetic relation (PI HAT calculated by PLINK<sup>58</sup> ≥ 874 875 0.1875) based on call rate, and (3) outliers from Japanese ancestry cluster based on the 876 principal component analysis with samples of 1KGP phase 3 data. For phenotype QC, we 877 excluded (1) the measurements in pregnant women, (2) those which took time from 878 sampling to biobanking  $\geq$  2 days, and (3) phenotypic outlier defined as log-transformed 879 measurements laying more than 4 SD from the mean for each metabolite. The participants 880 were genotyped with a custom SNP array for the Japanese population (i.e., Japonica Array 881 v2). For genotype QC, we excluded variants meeting any of the following criteria: (1) call 882 rate<98%, (2) *P* value for Hardy–Weinberg equilibrium<1.0 $\square$ × $\square$ 10<sup>-6</sup>, and (3) MAF<0.01. 883 The QCed genotype data were pre-phased by using SHAPEIT2 software (r837), and 884 imputed by using IMPUTE4 software (r300.3) with a combined reference panel of 1KGP phase3 (*n*=2,504) and population specific WGS data (i.e., 3.5KJPNv2; *n*=3,552)<sup>62</sup>. After 885 886 imputation, we excluded variants with imputation INFO<0.7.

887 For GWASs, we obtained the residuals from a linear regression model of each of log-transformed metabolites adjusted for age, age<sup>2</sup>, sex, time period from sampling to 888 889 biobanking, and top 20 genotype PCs. The residuals were then transformed by rank-based 890 inverse normalization. Association analysis of imputed genotype dosage with the normalized 891 residual of each metabolite was performed using PLINK2 software. We constructed the 892 Z-score matrices (W) of the Japanese metabolites GWASs (i.e., 206 rows) × 22,980 893 variants, in which we applied the same QC to the Z-scores and set the missing Z-scores to 894 zero again. We then performed the projection as described above.

895

896 Drug target enrichment analysis

To investigate whether disease-associated genes are systematically enriched in the targets of the approved drugs for the treatment of those diseases, the Genome for REPositioning drugs (GREP)<sup>48</sup> was used. A list of genes closest to the lead variants from GWAS, which was concatenated based on the alphabetical category of ICD10 (A to N), was used as an input gene set to test the enrichment for the target genes of approved drugs for diseases of a given ICD10 category.

## 904 References

905 1. Berger, D. A brief history of medical diagnosis and the birth of the clinical laboratory. 906 Part 1--Ancient times through the 19th century. MLO. Med. Lab. Obs. 31, (1999). 907 2. Organización Mundial de la Salud. International statistical classification of diseases 908 and related health problems, 10th revision (ICD-10). World Heal. Organ. (2016). 909 3. Denny, J. C. et al. Systematic comparison of phenome-wide association study of 910 electronic medical record data and genome-wide association study data. Nat. 911 Biotechnol. 31, 1102–1110 (2013). 912 4. Welter, D. et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait 913 associations. Nucleic Acids Res. 42, D1001-6 (2014). 914 5. Denny, J. C. et al. PheWAS: Demonstrating the feasibility of a phenome-wide scan to 915 discover gene-disease associations. Bioinformatics 26, 1205–1210 (2010). 916 Claussnitzer, M. et al. A brief history of human disease genetics. Nature 577, 179-189 6. 917 (2020).918 Martin, A. R. et al. Clinical use of current polygenic risk scores may exacerbate health 7. 919 disparities. Nat. Genet. 51, 584–591 (2019). 920 8. Tanigawa, Y. et al. Components of genetic associations across 2,138 phenotypes in 921 the UK Biobank highlight adipocyte biology. Nat. Commun. 10, 1–14 (2019). 922 Nagai, A. et al. Overview of the BioBank Japan Project: Study design and profile. J. 9. 923 Epidemiol. 27, S2-S8 (2017). 924 10. Bycroft, C. et al. The UK Biobank resource with deep phenotyping and genomic data. 925 Nature 562, 203–209 (2018). 926 11. Ritchie, M. D. et al. Robust Replication of Genotype-Phenotype Associations across 927 Multiple Diseases in an Electronic Medical Record. Am. J. Hum. Genet. 86, 560-572 928 (2010). 929 Ishigaki, K. et al. Large-scale genome-wide association study in a Japanese 12. 930 population identifies novel susceptibility loci across different diseases. Nat. Genet. 52, 931 669-679 (2020). 932 Kanai, M. et al. Genetic analysis of quantitative traits in the Japanese population links 13. 933 cell types to complex human diseases. Nat. Genet. 50, 390-400 (2018). 934 Akiyama, M. et al. Characterizing rare and low-frequency height-associated variants in 14. 935 the Japanese population. Nat. Commun. 10, 4393 (2019). 936 Zhou, W. et al. Efficiently controlling for case-control imbalance and sample 15. 937 relatedness in large-scale genetic association studies. Nat. Genet. 50, 1335–1341

938		(2018).
939	16.	Loh, P. R. et al. Efficient Bayesian mixed-model analysis increases association power
940		in large cohorts. <i>Nat. Genet.</i> <b>47</b> , 284–290 (2015).
941	17.	Bulik-Sullivan, B. et al. LD score regression distinguishes confounding from
942		polygenicity in genome-wide association studies. Nat. Genet. 47, 291–295 (2015).
943	18.	Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in
944		141,456 humans. <i>Nature</i> <b>581</b> , 434–443 (2020).
945	19.	Hagiya, H. et al. Trends in incidence and mortality of tuberculosis in Japan: A
946		population-based study, 1997-2016. Epidemiology and Infection vol. 147 (2019).
947	20.	Wu, Y. et al. Genome-wide association study of medication-use and associated
948		disease in the UK Biobank. <i>Nat. Commun.</i> <b>10</b> , 1–10 (2019).
949	21.	Gagliano Taliun, S. A. et al. Exploring and visualizing large-scale genetic associations
950		by using PheWeb. Nature Genetics vol. 52 550–552 (2020).
951	22.	Watanabe, K. et al. A global overview of pleiotropy and genetic architecture in
952		complex traits. <i>Nat. Genet.</i> <b>51</b> , 1339–1348 (2019).
953	23.	Canela-Xandri, O., Rawlik, K. & Tenesa, A. An atlas of genetic associations in UK
954		Biobank. <i>Nat. Genet.</i> <b>50</b> , 1593–1599 (2018).
955	24.	Pendergrass, S. A. et al. A phenome-wide association study (PheWAS) in the
956		Population Architecture using Genomics and Epidemiology (PAGE) study reveals
957		potential pleiotropy in African Americans. PLoS One 14, (2019).
958	25.	Verma, A. et al. PheWAS and Beyond: The Landscape of Associations with Medical
959		Diagnoses and Clinical Measures across 38,662 Individuals from Geisinger. Am. J.
960		<i>Hum. Genet.</i> <b>102</b> , 592–608 (2018).
961	26.	Field, Y. et al. Detection of human adaptation during the past 2000 years. Science
962		<i>(80 ).</i> <b>354</b> , 760–764 (2016).
963	27.	Okada, Y. et al. Deep whole-genome sequencing reveals recent selection signatures
964		linked to evolution and disease risk of Japanese. Nat. Commun. 9, 1631 (2018).
965	28.	Qi, H. et al. Discovery of susceptibility loci associated with tuberculosis in Han
966		Chinese. Hum. Mol. Genet. 26, 4752–4763 (2017).
967	29.	Sveinbjornsson, G. et al. HLA class II sequence variants influence tuberculosis risk in
968		populations of European ancestry. Nat. Genet. 48, 318–322 (2016).
969	30.	Baldini, C., Ferro, F., Mosca, M., Fallahi, P. & Antonelli, A. The association of Sjögren
970		syndrome and autoimmune thyroid disorders. Frontiers in Endocrinology vol. 9 121
971		(2018).
972	31.	Nakao, M. et al. ABO blood group alleles and the risk of pancreatic cancer in a

973 Japanese population. Cancer Sci. 102, 1076–1080 (2011). 974 32. Edgren, G. et al. Risk of gastric cancer and peptic ulcers in relation to ABO blood type: 975 A cohort study. Am. J. Epidemiol. 172, 1280–1285 (2010). 976 33. Bulik-Sullivan, B. et al. An atlas of genetic correlations across human diseases and 977 traits. Nat. Genet. 47, 1236–1241 (2015). 978 34. Anttila, V. et al. Analysis of shared heritability in common disorders of the brain. 979 Science (80-. ). 360, (2018). 980 Shi, H., Mancuso, N., Spendlove, S. & Pasaniuc, B. Local Genetic Correlation Gives 35. 981 Insights into the Shared Genetic Architecture of Complex Traits. Am. J. Hum. Genet. 982 **101**, 737–751 (2017). 983 36. Burren, O. S. & Wallace, C. Informed dimension reduction of clinically-related 984 genome-wide association. *bioRxiv* (2020). 985 37. Chasman, D. I., Giulianini, F., Demler, O. V. & Udler, M. S. Pleiotropy-Based 986 Decomposition of Genetic Risk Scores: Association and Interaction Analysis for Type 987 2 Diabetes and CAD. Am. J. Hum. Genet. 106, 646-658 (2020). 988 38. McLean, C. Y. et al. GREAT improves functional interpretation of cis-regulatory 989 regions. Nat. Biotechnol. 28, 495-501 (2010). 990 39. Meuleman, W. et al. Index and biological spectrum of human DNase I hypersensitive 991 sites. Nature 584, 244–251 (2020). 992 40. GTEx Consortium, F. et al. Genetic effects on gene expression across human tissues. 993 Nature 550, 204–213 (2017). 994 41. Shin, S. Y. et al. An atlas of genetic influences on human blood metabolites. Nat. 995 Genet. 46, 543-550 (2014). 996 42. Portincasa, P. & Wang, D. Q. H. Intestinal absorption, hepatic synthesis, and biliary 997 secretion of cholesterol: Where are we for cholesterol gallstone formation? 998 Hepatology vol. 55 1313–1316 (2012). 999 43. Vessey, D. A. The biochemical basis for the conjugation of bile acids with either 1000 glycine or taurine. Biochem. J. 174, 621-626 (1978). 1001 Coombs, R. R. A. & Gell, P. G. . The Classification of Allergic Reactions Underlying 44. 1002 Disease. in Clinical Aspects of Immunology 317–337 (1963). 1003 45. Stone, K. D., Prussin, C. & Metcalfe, D. D. IgE, mast cells, basophils, and eosinophils. 1004 J. Allergy Clin. Immunol. 125, S73 (2010). 1005 46. Kobayashi, K., Kaneda, K. & Kasama, T. Immunopathogenesis of delayed-type 1006 hypersensitivity. Microsc. Res. Tech. 53, 241-245 (2001). 1007 47. Okada, Y. et al. Genetics of rheumatoid arthritis contributes to biology and drug

1008 discovery. *Nature* **506**, 376–381 (2014).

1009 48. Sakaue, S. & Okada, Y. GREP: Genome for REPositioning drugs. *Bioinformatics* 35, 3821–3823 (2019).

- 1011 49. Sakaue, S. *et al.* Trans-biobank analysis with 676,000 individuals elucidates the
  1012 association of polygenic risk scores of complex traits with human lifespan. *Nat. Med.*1013 26, 542–548 (2020).
- 1014 50. McLaren, W. *et al.* The Ensembl Variant Effect Predictor. *Genome Biol.* **17**, 122 (2016).
- 1016 51. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: Fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* **26**, 2190–2191 (2010).
- Brown, B. C., Ye, C. J., Price, A. L. & Zaitlen, N. Transethnic Genetic-Correlation
  Estimates from Summary Statistics. *Am. J. Hum. Genet.* **99**, 76–88 (2016).
- 1020 53. Raychaudhuri, S. *et al.* Five amino acids in three HLA proteins explain most of the
  1021 association between MHC and seropositive rheumatoid arthritis. *Nat. Genet.* 44,
  1022 291–296 (2012).
- 1023 54. Hirata, J. *et al.* Genetic and phenotypic landscape of the major histocompatibility 1024 complex region in the Japanese population. *Nat. Genet.* **51**, 470–480 (2019).
- 1025 55. Jia, X. *et al.* Imputing Amino Acid Polymorphisms in Human Leukocyte Antigens.
  1026 *PLoS One* **8**, e64683 (2013).
- 1027 56. Zheng, J. *et al.* LD Hub: A centralized database and web interface to perform LD score
  1028 regression that maximizes the potential of summary level GWAS data for SNP
- 1029 heritability and genetic correlation analysis. *Bioinformatics* **33**, 272–279 (2017).
- 1030 57. Gazal, S. *et al.* Linkage disequilibrium-dependent architecture of human complex traits
  1031 shows action of negative selection. *Nat. Genet.* 49, 1421–1427 (2017).
- 1032 58. Purcell, S. et al. PLINK: A Tool Set for Whole-Genome Association and
- 1033 Population-Based Linkage Analyses. Am. J. Hum. Genet. 81, 559–575 (2007).
- 1034 59. Finucane, H. K. *et al.* Heritability enrichment of specifically expressed genes identifies
  1035 disease-relevant tissues and cell types. *Nat. Genet.* **50**, 621–629 (2018).
- Rüeger, S., McDaid, A. & Kutalik, Z. Evaluation and application of summary statistic
  imputation to discover new height-associated loci. *PLoS Genet.* 14, e1007371 (2018).
- 1038 61. Kuriyama, S. et al. The Tohoku Medical Megabank Project: Design and mission. J.
- 1039 *Epidemiol.* **26**, 493–511 (2016).
- 1040 62. Tadaka, S. *et al.* JMorp: Japanese Multi Omics Reference Panel. *Nucleic Acids Res.*1041 46, D551–D557 (2018).
- 1042

URLs

1045	-	SDS	values	in	UK10	К р	provided		су	Pritcha		s la	ab;		
1046		http://web.stanford.edu/group/pritchardlab/UK10K-SDS-values.zip													
1047	-	Summary	statistics of	BBJ,	Europe	an, and	cross-p	opulati	on r	neta-a	nalysis	GWAS	s;		
1048		https://pheweb.jp/													
1049	-	Summary	statistics	of	biomark	ker GW	/ASs	in U	KB	by	Neale's	s lab	;		
1050		http://www.nealelab.is/uk-biobank/ukbround2announcement													
1051	-	LDSC software; https://github.com/bulik/ldsc													
1052	-	FinnGen release 3 data; https://www.finngen.fi/en/access_results													
1053	-	dbSNP; https://www.ncbi.nlm.nih.gov/snp/													
1054	-	World	Health	0	organizati	on,	Globa	al	Tub	perculo	osis	Repo	ort;		
1055		https://www.who.int/tb/publications/global_report/en/													
1056	-	Metabolite	e GWAS	sun	nmary	statistic	s in	the	E	uropea	an po	opulatio	ns:		
1057		http://meta	abolomics.he	Imhol	tz-muenc	chen.de/g	gwas/ind	dex.php	o?tas	sk=dov	wnload				